~~<i id='E918BE789A'><strike id='E918BE789A'><tt id='E918BE789A'><pre id='E918BE789A'></pre></tt></strike></i>~~

Home» knowledge» entertainment

entertainment

author：Wikipedia 2025-09-27 18:29:33 Page View：72931

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Breakthrough Alzheimer’s drugs are inaccessible in rural states
Next article： Dobbs anniversary: the lost opportunity of abortion as health care

leisure time

Bright Health sells Medicare Advantage business to Molina

BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

Washington mulls new rules to avert another Change Healthcare

AdobeWashingtoniscrackingdownonthetechnologyrunningbehindthescenesinhealthcarefollowingadebilitating

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

ThisistheinauguraleditionofAdam’sBiotechScorecard,anewsubscriber-onlynewsletter.STAT+subscriberscans